




FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



Study drug period

- Drug administered every 6h (1st dose within 6h of surgery)
- VAS pain intensity and pain relief scores (5, 10, 15, 30, 45 min, 1, 2, 3, 5, 6h, and every subsequent 3-hour interval to 48h, then every 6-hour interval to 120h, if necessary)
- Lab tests and ECG 24h after 1st dose: patient global evaluation every 24h following 1st dose
- Vital signs immediately before and 30 min after each dose
- Injection site thrombophlebitis evaluation immediately before and 1h after each dose

FIG. 6




FIG. 7




FIG. 8





FIG. 9



11/19




FIG. 11




FIG. 12

13/19




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B

17/19




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B